Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission - Paschka, Peter; Müller, Martin Christian; Merx, Kirsten; Kreil, Sebastian; Schoch, C.; Lahaye, T.; Weißer, Andreas; Petzold, A.; König, H.; Berger, Ute; Gschaidmeier, Harald; Hehlmann, Rüdiger; et al. (Leukemia, 2003)
Gesehen am 16.05.2022